References for Ovarian Cancer - Natural Medical Protocols

Below are supplemental abstracts and references of research that support the conclusions on the treatment for Ovarian Cancer

Garlic and Onions

Galeone C, et al. "Onion and garlic use and human cancer." Am J Clin Nutr. 2006;84(5):1027-32.

Schultz M, et al. "Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition." Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2531-5.

Vegetables, Fat

Zhang M, et al. "Diet and ovarian cancer risk: a case-control study in China." Br J Cancer. 2002;86:712-717.

McCann SE, et al. "Intakes of selected nutrients and food groups and risk of ovarian cancer." Nutr Cancer. 2001;39(1):19-28.

Risch, et al. "Dietary fat intake and risk of epithelial ovarian cancer." J Nat Cancer Inst. September21,1994;86(18):1409-1415.

Legumes

Pawlega J, et al. "Ovarian cancer and selected life style habits." Ginekologia Polska. January,1995;66(1):41-5.

Dairy Products

Larsson SC, et al. "Milk and lactose intakes and ovarian cancer risk in the Swedish mammography cohort." Am J Clin Nutr. 2004;80:1353-1357.

Johnson K. "Dairy products linked to ovarian cancer risk." Fam Prac News. June15,2000:8.

Kushi LH, et al. "Prospective study of diet and ovarian cancer." Am J Epidemiol. 1999;149(1):21-31.

Pawlega J, et al. "Ovarian cancer and selected life style habits." Ginekologia Polska. January,1995;66(1):41-5.

Liebman B. "Crying over milk." Nutr Action. December,1992;1:6-7.

Cramer DW, et al. "Galactose consumption and metabolism in relation to the risk of ovarian cancer." Lancet. 2:66-71,1989.

Tobacco, Alcohol, Coffee and Sugar

Goodman MT, et al. "Association of caffeine intake and CYP1A2 genotype with ovarian cancer." Nutr Cancer. 2003;46(1):23-29.

Rossi-Fanelli F, et al. "Abnormal substrate metabolism and nutritional strategies in cancer management." J Parent Enteral Nutr. 1991;15(6):680-3.

Vitamin and Mineral References

Beta Carotene

Cramer DW, et al. "Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women." Int J Cancer. 2001;94:128-134.

Engle A, et al. "Nutritional factors and ovarian cancer." Nutr Cancer. 1991;15(3&4):240-247.

Vitamin A

Pence BC. "Nutritional factors in women's cancers: breast, cervical, endometrial and ovarian." The Nutritional Concerns of Women. 2004;17:341-363. edited by Dorothy Klimis-Zacas and Ira Wolinsky.

Linder MC, Ed. Nutritional Biochemistry and Metabolism. 2 ed. Elsevier Science Publishing Co. Inc; NY, NY; 1991.

Vitamin C

Drisko JA, et al. "The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer." J Am Coll Nutr. 2003;22(2):118-123.

Conklin KA. "Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects." Nutr Cancer. 2000;37(1):1-18.

Henson DE, et al. "Ascorbic acid: Biologic functions and relation to cancer." J Natl Cancer Inst. 1991;83(8):547-50.

Cameron E, Campbell A. "Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer." Med Hypo. 1991;36(3):185-9.

Vitamin D

Tworoger SS, et al. "Plasma 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d and risk of incident ovarian cancer." Cancer Epidemiol Biomarkers Prev. 2007;16(4):783-8.

Grant WB. "The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival." Anticancer Research. 2006;26(4A):2605-2614.

Garland CF, et al. "The role of vitamin D in cancer prevention." Am J Public Health. 2005;Dec 27.

Salazar-Martinez E, et al. "Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico." Oncol. 2002;63:151-157.

Saunders DE, et al. "Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone." Anticancer Drugs. August,1995;6:4,562-9.

Saunders DE, et al. "Receptors for 1,25-dihydroxyvitamin D 3 in gynecologic neoplasms." Gynecol Oncol. February,1992;44:2,131-6.

Vitamin E

Bidoli E, et al. "Micronutrients and ovarian cancer: a case-control study in italy." Ann Oncol. 2001;12:1589- 1593.

Fleischauer AT, et al. "Dietary antioxidants, supplements, and risk of epithelial ovarian cancer." Nutr Cancer. 2001;40(2):92-98.

Marz RB. Medical Nutrition from Marz, 2nd ed. Omni Press; Portland, OR; 1997:182-83.

Selenium

Willett WC, Stampfer MJ. "Selenium and human cancer." Acta Pharmacol Toxicol. 1989;59(Suppl7):240-7.

Willett WC, et al. "Prediagnostic serum selenium and risk of cancer." Lancet. July16,1983;2(8342):130-4.

Supplement References

Melatonin

Boik J. Cancer and Natural Medicine. Oregon Medical Press; Princeton, MN; 1995,75-6.

Crespo D, et al. "Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells." J Pineal Res. May,1994;16:4,215-22.

Brackowski R, et al. "Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin." J Biol Regul Homeost Agents. July-September,1994;8:3,77-80.

Moss RW. Cancer Therapy: The Independent Consumer's Guide to Non-Toxic Treatment and Prevention. Equinox Press; NY, NY; 1994;461.

Maestroni GJ. "The immunoneuroendocrine role of melatonin." J Pineal Res. January,1993;14(1):1-10.

Kerenyi NA, et al. "Why the incidence of cancer is increasing: the role of 'light pollution'." Med Hypoth. October,1990;33(2):75-8.

Quercetin

Prajda N, et al. "Linkage of reduction in 1-phosphatidylinositol 4-kinase activity and inositol 1,4,5-triphosphate concentration in human ovarian carcinoma cells treated with quercetin." Life Sci. 1995;56(19);1587-93.

Scambia G, et al. "Quercetin enhances transforming growth factor beta 1 secretion by human ovarian cancer cells." Int J Cancer. April15,1994;57:2,211-5.

Larocca LM, et al. "Growth-inhibitory effect of quercetin and presence of type II estrogen binding sites in primary human transitonal cell carcinomas." J Urol. September,1994;152:3,1029-33.

Ferrandina G, et al. "Type II estrogen-binding sites in human ovarian cancer: correlation with estrogen, progesterone, and epidermal growth factor receptor." Gynecol Oncol. April,1993;49:1,67-72.

Pizzorno, JE, Murray, MT. A Textbook of Natural Medicine. Bastyr University Publications; Seattle, WA; Quercetin V:Querc-1 Vol.2;1993.

Scambia G, et al. "Quercetin inhibits the growth of multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites." Cancer Chemother Pharmacol. 1991;28:4,255-8.

Scambia G, et al. "Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells." Br J Cancer. December,1990;62:6,942-6.

Scambia G, et al. "Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids." Intl J Cancer. December15,1990;46:6,1112-6.

Botanical References

Ginkgo biloba

Ye B, et al. "Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence." Cancer Lett. 2006;Dec26.

Hosxey Formula

Brinker F. "The Hoxsey treatment: cancer quackery or effective physiological adjuvant?" J Nat Med. 1996;6(1):9-23.

Boik J. Cancer and Natural Medicine. Oregon Medical Press; Princeton, MN; 1995,113,117,157-9.

Wang LK, et al. "Inhibition of topoisomerase I function by nitidine and fagaronine." Chem Res Toxicol. November-December,1993;6:6,813-8.

Suzuki F, et al. "Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots." In Vivo. 1992;6:589-96.

Wren RC. Potter's New Encyclopedia of Botanical Drugs and Preparations. The CW Daniel Company LTD; Essex CB10 1JP, England; 1988,46,49,61-62,224,230,233,282.

Morita K, et al. "Chemical nature of a desmutagenic factor from burdock (Arctium lappa Linne)." Agric Biol Chem. 1985;49(4):925-32.

Morita K, et al. "A desmutagenic factor isolated from burdock (Arctium Lappa Linne)." Mutation Res. 1984;129:25-31.

Cushman M, et al. "Synthesis and biological activity of structural analogues of the anticancer benzophenanthridine alkaloid nitidine chloride." J Med Chem. April,198427:4,544-7.

Kumazawa Y, et al. "Activation of peritoneal macrophages by berberine-type alkaloids in terms of induction of cytostatic activity." Intl J Immunopharmac. 1984;6(6):587-92.

Bodger MF, et al. "Mitogenic proteins of pokeweed. I. Purification, characterization and mitogenic activity of two proteins from pokeweed (Phytolacca octandra)." Immunol. 1979;37:792.

Bodger MF, et al. "Mitogenic proteins of pokeweed. II. The differentiation of human peripheral blood B lymphocytes stimulated with purified pokeweed mitogens (Po-2 and Po-6) from pokeweed (Phytolacca octandra)." Immunol. 1979;37:793-99.

McPherson A. Toxic Plants. Ed. AD Kinghorn; Columbia Press; 1979.

Kupchan SM, Karim A. "Tumor inhibitors 114: Aloe emodin: antileukemic principle isolated from Rhamnus frangula" L. Lloydia. 1976;39,223-4.

Yoloyama K, et al. "Purification and biological activities of pokeweed (Phytolacca americana) mitogens." Biochem Biophys Acta. 1976;427:443-52.

Shvarev IF, et al. "Effect of triterpenoid compounds from glycyrrhiza glabra on experimental tumors. Voprosy Izucheniya Ispol'zovaniy." Solodki v SSSR, Akademi Nauk SSSR; 1966;167-70.

Foldeak S, Dombradi GA. "Tumor-growth inhibiting substances of plant origin. Isolation of the active principle of Arctium lappa." Acta Univ Szeged, Acta Phys Chem. 1964;10:91-3.

Belkin M, et al. "Swelling and vacuolization induced in ascites tumor cells by polysaccharides from higher plants." Cancer Res. 1959;19:1050-62.

Schmitz H. "The influence of berberine on cellular metabolism." Z. Krebsforsch. 1950;57:137-41.

Yew Tree Tea

Kohn EC, et al. "Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer." J Natl Cancer Inst. January4,1996;86(1):18-24.

McGuire WP. "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer." N Eng J Med (comment). January4,1996;334(1):50-1.

Snyder LA. "Description and Natural History of the English and Pacific Yews." BioTech Resources. 1996.

Willis R. "Facts About Montana Yew." Bighorn Botanicals. 1996.

Suffness M, ed. "Taxol Science and Applications." Am Bot Council. 1995.

Milas L, et al. "Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol." Cancer Chemother Pharmacol. l995;35(4):297-303.

Horwitz SB. "Taxol (paclitaxel): mechanisms of action." Ann Oncol. 1994;5;Suppl6:S3-6.

Taniki T, et al. "Synergistic action of taxol and tiazofurin in human ovarian, pancreatic and lung carcinoma cells." Cancer Biochem Biophys. September,1993;13(4):295-302.

Homeopathy References

Morrison R.Desktop Guide to Keynotes and Confirmatory Symptoms.Hahnemann Clinic Publishing; Albany, CA; 1993.

Murphy R.Homeopathic Medical Repertory.Hahnemann Academy of North America; Pagosa Springs, CO; 1993.

Phatak SR. A Concise Repertory of Homoeopathic Medicines. B. Jain Publishers Pvt. Ltd.; New Delhi, India; 1992.

Kruzel T. The Homeopathic Emergency Guide.North Atlantic Books; Berkeley, CA; 1992.

Kent JT. Repertory of the Homeopathic Materia Medica.B. Jain Publishers (P) LTD; New Delhi, India; 1991.

Boericke W. Materia Medica with Repertory, 9th Ed..Boericke & Tafel, Inc.; Santa Rosa, CA; 1927.

Other Treatment References

CA 125

"Chemical tip-off to ovarian cancer." Sci News. June,1991;139:347.

Alternative Therapies

Crouse LV. "Naturopathic treatment of ovarian cancer." J Naturopathic Med. 1997;Vol7,Number1.

Sunlight

Freedman DM, et al. "Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study." Occup Environ Med. 2002;59:257-262.